TY - JOUR
T1 - Endoscopic techniques for treating gastroesophageal reflux
AU - Genere, Juan Reyes
AU - Wang, Kenneth K.
N1 - Publisher Copyright:
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Purpose of review Nearly, a third of patients with medically refractory gastroesophageal reflux disease (GERD) will desire an additional nonsurgical treatment option. Recently, endoscopic therapy has been reintroduced as a minimally invasive antireflux barrier treatment, after addressing prior efficacy and safety concerns. Over the last two decades, additional experience and new technologies have resulted in devices and protocols with favorable short-term outcomes and safety profiles. The current literature in endoscopic antireflux therapies covers new devices, long-term follow-up data and further safety experience. This review discusses the endoscopic antireflux devices on the market and most recent studies in this area. Recent findings Quality of life and reflux symptom score improvement is observed in 73–90% of patients through a 36–48 month follow-up period, with 41–77% remaining off all reflux medicines. Composite data from several thousand cases indicate a low rate (0.93–2.4%) of serious complications and no late adverse effects, including gas-bloat syndrome. Summary In this review, we describe the four endoscopic antireflux devices on market and summarize the current data in the literature. The short and long-term data demonstrate durable symptom improvement and favorable safety profile. Endoscopic antireflux treatment should be considered in the management of GERD.
AB - Purpose of review Nearly, a third of patients with medically refractory gastroesophageal reflux disease (GERD) will desire an additional nonsurgical treatment option. Recently, endoscopic therapy has been reintroduced as a minimally invasive antireflux barrier treatment, after addressing prior efficacy and safety concerns. Over the last two decades, additional experience and new technologies have resulted in devices and protocols with favorable short-term outcomes and safety profiles. The current literature in endoscopic antireflux therapies covers new devices, long-term follow-up data and further safety experience. This review discusses the endoscopic antireflux devices on the market and most recent studies in this area. Recent findings Quality of life and reflux symptom score improvement is observed in 73–90% of patients through a 36–48 month follow-up period, with 41–77% remaining off all reflux medicines. Composite data from several thousand cases indicate a low rate (0.93–2.4%) of serious complications and no late adverse effects, including gas-bloat syndrome. Summary In this review, we describe the four endoscopic antireflux devices on market and summarize the current data in the literature. The short and long-term data demonstrate durable symptom improvement and favorable safety profile. Endoscopic antireflux treatment should be considered in the management of GERD.
KW - Antireflux therapy
KW - Endoscopic plication
KW - Gastroesophageal reflux disease endotherapy
KW - Minimally invasive
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=85056484965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056484965&partnerID=8YFLogxK
U2 - 10.1097/MOG.0000000000000468
DO - 10.1097/MOG.0000000000000468
M3 - Article
C2 - 30067561
AN - SCOPUS:85056484965
SN - 0267-1379
VL - 34
SP - 288
EP - 294
JO - Current Opinion in Gastroenterology
JF - Current Opinion in Gastroenterology
IS - 5
ER -